The allosteric TYK2 mechanism that sets deucravacitinib apart

Deucravacitinib (Sotyktu) achieves its selectivity not by competing for the ATP-binding catalytic site shared across the JAK kinase family, but by binding the regulatory pseudokinase domain of TYK2 — a structurally distinct allosteric pocket that locks the enzyme in an inactive conformation. This single mechanistic distinction separates deucravacitinib from the first generation of JAK inhibitors and underpins its differentiated clinical profile across immune-mediated diseases.

Conventional JAK inhibitors — including tofacitinib, baricitinib, and upadacitinib — competitively occupy the ATP-binding catalytic domain and, because this domain is structurally conserved across JAK1, JAK2, JAK3, and TYK2, they inevitably exert activity across multiple family members. The resulting broad JAK suppression contributes to both therapeutic efficacy and a well-documented adverse-effect profile that includes infection risk, haematological changes, and cardiovascular signals that have attracted regulatory scrutiny from bodies including the European Medicines Agency.

Deucravacitinib’s pseudokinase-domain binding strategy circumvents this problem. The pseudokinase (also called the JH2 or regulatory domain) of TYK2 is structurally divergent from the equivalent domains of JAK1, JAK2, and JAK3, providing a selectivity handle that ATP-competitive molecules cannot exploit. The result is potent TYK2 inhibition with substantially reduced activity against the other three JAK family members — a profile that translates, in preclinical and clinical data, into attenuation of IL-12, IL-23, and type I interferon signalling without the broader immunosuppressive footprint of pan-JAK inhibition.

From psoriasis approval to a broader autoimmune thesis

Deucravacitinib’s regulatory approval for moderate-to-severe plaque psoriasis validated the allosteric TYK2 inhibition concept in a human disease setting for the first time, demonstrating that selectively blocking IL-23 and IL-12 signalling through TYK2 pseudokinase inhibition produces clinically meaningful skin clearance. That approval also established the safety and tolerability reference point from which expansion into other immune-mediated conditions could be evaluated.

Plaque psoriasis is driven substantially by the IL-23/Th17 axis — a pathway in which TYK2 plays a critical transducing role downstream of IL-23 receptor engagement. The efficacy signal observed in psoriasis Phase III trials (the POETYK PSO programme) therefore served as proof-of-concept not just for the molecule, but for the entire mechanistic premise: that allosteric pseudokinase-domain inhibition can produce durable, selective cytokine pathway suppression in a chronic inflammatory disease. According to WHO, psoriasis affects approximately 125 million people globally, giving the approved indication substantial commercial and scientific weight.

The mechanistic logic for indication expansion is straightforward: TYK2 is not a psoriasis-specific kinase. It is a broadly expressed signalling node that transduces cytokine signals relevant to multiple autoimmune diseases. IL-12 and IL-23 are implicated in psoriatic arthritis, inflammatory bowel disease, and several other conditions. Type I interferons — the third major cytokine class signalling through TYK2 — are centrally dysregulated in systemic lupus erythematosus, dermatomyositis, and Sjögren’s syndrome. Each of these represents a potential expansion indication, and each is supported by the same mechanistic rationale that drove the psoriasis programme.

“TYK2 is not a psoriasis-specific kinase — it is a broadly expressed signalling node transducing IL-12, IL-23, and type I interferon signals relevant to multiple autoimmune diseases, making allosteric inhibition a platform mechanism rather than a single-indication strategy.”

Why SLE is the critical next frontier for TYK2 inhibition

Systemic lupus erythematosus (SLE) represents one of the most mechanistically compelling expansion targets for deucravacitinib because the disease is characterised by chronic, pathogenic elevation of type I interferons — the very cytokine class most selectively attenuated by TYK2 pseudokinase inhibition. The type I interferon signature in SLE is not incidental; it is a central driver of disease activity, organ damage, and the autoantibody production that defines lupus pathogenesis.

TYK2 sits at the intersection of multiple SLE-relevant cytokine pathways. Beyond type I interferons, TYK2 also transduces IL-12 signalling, which drives Th1 polarisation and contributes to the inflammatory milieu in lupus nephritis and other organ manifestations. The ability of deucravacitinib to simultaneously attenuate both the interferon and IL-12 arms of TYK2-dependent signalling is therefore particularly relevant in SLE, where disease heterogeneity and multi-organ involvement require broad but targeted immunomodulation.

Current SLE treatments — including hydroxychloroquine, corticosteroids, mycophenolate mofetil, and biologics such as belimumab and anifrolumab — leave a substantial proportion of patients with inadequately controlled disease. Anifrolumab, which directly blocks the type I interferon receptor (IFNAR), demonstrated that interferon pathway suppression is therapeutically effective in SLE, providing important clinical validation for the biological hypothesis that also supports TYK2 inhibition. The difference is mechanistic: anifrolumab is a monoclonal antibody targeting the receptor, while deucravacitinib acts intracellularly on the kinase that transduces the receptor signal — a small-molecule approach that offers oral administration and potentially broader pathway coverage through simultaneous IL-12 attenuation.

The POETYK SLE programme and Phase III pipeline signals

The POETYK SLE programme represents the pivotal Phase III evaluation of deucravacitinib in systemic lupus erythematosus, building directly on the mechanistic rationale established by the POETYK PSO trials in psoriasis. The programme is designed to assess whether selective TYK2 inhibition — and specifically the attenuation of the type I interferon signature — translates into clinically meaningful disease control in SLE patients, as measured by validated composite endpoints including SRI-4 (SLE Responder Index-4) and BICLA (British Isles Lupus Assessment Group-based Composite Lupus Assessment).

The POETYK SLE programme sits within a broader wave of targeted immunology trials in lupus that has been encouraged by the regulatory success of anifrolumab and the growing scientific consensus — reflected in publications indexed by PubMed — that the type I interferon pathway is a valid, druggable target in SLE. What distinguishes the TYK2 inhibitor approach is the oral, small-molecule format and the simultaneous coverage of both interferon and IL-12 branches of TYK2-dependent signalling.

Trial design considerations and endpoint selection

Phase III SLE trials face well-documented design challenges, including high placebo response rates, heterogeneous patient populations, and the need for composite endpoints that capture multi-organ disease activity. The choice of SRI-4 and BICLA as co-primary or primary endpoints in recent SLE programmes reflects regulatory and scientific consensus on what constitutes a meaningful treatment effect in this complex disease — a consensus shaped by guidance from bodies including the FDA and EMA.

For deucravacitinib specifically, biomarker enrichment strategies — selecting patients with elevated interferon gene expression signatures — may offer a path to cleaner efficacy signals, given that TYK2’s most differentiated mechanistic contribution in SLE is interferon pathway suppression. Whether the POETYK SLE programme incorporates such enrichment, or pursues a broader unselected SLE population, will significantly influence the interpretation of readout data and the eventual label, if approved.

Expansion beyond SLE: psoriatic arthritis and other immune-mediated diseases

Psoriatic arthritis (PsA) is the other major Phase III expansion target for deucravacitinib, supported by the IL-23/Th17 axis that drives both skin and joint disease in psoriatic conditions — the same pathway already validated by the psoriasis approval. The expansion of the POETYK programme into PsA therefore represents a lower-risk, mechanistically continuous step compared with the SLE indication, where the primary driver shifts from IL-23 to type I interferons. Beyond SLE and PsA, the TYK2 mechanistic rationale also extends to inflammatory bowel disease (Crohn’s disease and ulcerative colitis, where IL-12 and IL-23 are established targets), dermatomyositis, and Sjögren’s syndrome — all conditions where TYK2-dependent cytokine pathways contribute to pathogenesis.

Competitive landscape and the evolving TYK2 inhibitor class

Deucravacitinib currently occupies a unique position as the only approved allosteric TYK2 inhibitor, but the competitive landscape is evolving as the mechanistic validation provided by the psoriasis approval has attracted additional entrants to the TYK2 inhibitor class. Several programmes are pursuing both allosteric pseudokinase-domain approaches and, in some cases, ATP-competitive TYK2-selective strategies — the latter attempting to achieve TYK2 selectivity through catalytic-domain binding by exploiting subtle structural differences between TYK2 and other JAK family members.

The patent landscape around TYK2 inhibition has expanded substantially since the initial disclosure of the pseudokinase-domain binding concept. Patent offices including the EPO have received filings covering novel allosteric binding modes, combination approaches pairing TYK2 inhibition with other immunological targets, and formulation innovations aimed at improving bioavailability and dosing convenience. Tracking this patent activity — across assignees, filing dates, and claim scope — provides an early signal of where the competitive frontier is moving before clinical data become public.

For R&D leaders and IP professionals monitoring this space, the key intelligence questions are: which assignees are filing continuation patents around the TYK2 pseudokinase binding pocket; which companies are pursuing combination strategies pairing TYK2 inhibition with PD-1/PD-L1, BAFF, or other lupus-relevant targets; and what formulation or dosing innovations are being protected that could extend exclusivity beyond the core compound patent. PatSnap Eureka’s drug intelligence platform surfaces exactly these signals from live patent databases, enabling teams to map the competitive frontier before clinical data crystallises it.